Hepatopulmonary Syndrome and Portopulmonary Hypertension: What's new?

Acta Gastro-Enterologica Belgica

Volumn 70, Issue 2, 2007, Pages 203-209

  Colle, Isabelle ^a   Van Steenkiste, Christophe ^a   Geerts, Anja ^a   Van Vlierberghe, Hans ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN I; BERAPROST; BOSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ILOPROST; NITROUS OXIDE; NORFLOXACIN; OXYGEN; PENTOXIFYLLINE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; TREPROSTINYL; UNCLASSIFIED DRUG;

ANGIOGENESIS; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEPATOPULMONARY SYNDROME; HUMAN; HYPOXEMIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LUNG ARTERIOVENOUS SHUNT; NONHUMAN; PORTAL HYPERTENSION; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; SPLANCHNIC BLOOD FLOW; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; DIAGNOSIS, DIFFERENTIAL; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEPATOPULMONARY SYNDROME; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PHOSPHODIESTERASE INHIBITORS; PROGNOSIS; PULMONARY WEDGE PRESSURE; VASODILATOR AGENTS;

EID: 34447520533     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (67)

1. RODRIGUEZ-ROISIN R., KROWKA M., HERVÉ PH., FALLON M., on behalf of the ERS task force-PHD Scientific Committee. Highlights of the ERS task force on pulmonary-hepatic vascular disorders. J. Hepatol., 2005, 42 : 924-927.
2. SCHENK P., SCHONIGER-HEKELE M., FUHRMANN V., MADL C., SILBERHUMER G., MULLER C. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology, 2003, 125 : 1042-1052.
3. HOPKINS W.E., WAGGONER A.D., BARZILAI B. Frequency and significance of intrapulmonary right-to-left shunting in end-stage hepatic disease. Am. J. Cardiol., 1992, 70 : 516-519.
4. LUO B., ABRAMS G.A., FALLON MB. Endothelin-1 in the rat bile duct ligation model of hepatopulmonary syndrome : correlation with pulmonary dysfunction. J. Hepatol., 1998, 29 : 571-578.
5. LIU L., ZHANG M., LUO B., ABRAMS A., FALLON M. Biliary cyst fluid from common bile duct-ligated rats stimulates endothelial nitric oxide synthase in pulmonary artery endothelial cells : a potential role in hepatopulmonary syndrome. Hepatology, 2001, 33 : 722-727.
6. SZTRYMF B., LIBERT J.M., MOUGEOT C., LEBREC D., MAZMANIAN M., HUMBERT M., HERVE P. Cirrhotic rats with bacterial translocation have higher incidence and severity of hepatopulmonary syndrome. J. Gastroenterol. Hepatol., 2005, 20 : 1538-1544.
7. ZHANG H., HAN D., WANG X., ZHAO Y., ZHOU X., ZHAO H. Experimental study on the role of endotoxin in the development of hepatopulmonary syndrome. World J. Gastroenterol., 2005, 11 : 567-572.
8. LUO B., LIU L., TANG L., ZHANG J., LING Y., FALLON M. ET-1 and TNF-α in HPS : analysis in prehepatic portal hypertension and biliary and nonbiliary cirrhosis in rats. Am. J. Physiol. Gastrointest. Liver Physiol., 2004, 286 : G294-G303.
9. FILEP J.G. Endothelin peptides : biological actions and pathophysiological significance in the lung. Life Sci., 1993, 52 : 119-133.
10. LUO B., LIU L., TANG L., ZHANG J., STOCKARD C., GRIZZLE W., FALLON M. Increased pulmonary vascular endothelin-B receptor expression and responsiveness to endothelin 1 in cirrhotic and portal hypertensive rats : a potential mechanism in experimental hepatopulmonary syndrome. J. Hepatol., 2003, 38 : 556-563.
11. SCHROEDER R.A., EWING C.A., SITZMANN J., KUO P. Pulmonary expression of iNOS and HO-1 protein is upregulated in a rat model of prehepatic portal hypertension. Dig. Dis. Sci., 2000, 45 : 2405-2410.
12. ZHANG J., LING Y., LUO B. et al. Analysis of pulmonary heme oxygenase-1 and nitric oxide synthase alterations in experimental hepatopulmonary syndrome. Gastroenterology, 2003, 125 : 1441-1451.
13. YOL S., ERIKOGLU M., TOPRAK S., TAVLI S., TAVLI L. The effects of serum estrogen levels on hypoxaemia and blood nitric oxide levels in experimental hepatopulmonary syndrome. Hepatology Research, 2005, 33 : 7-13.
14. CREMONA G., HIGENBOTTAM T.W., MAYORAL V et al. Elevated exhaled nitric oxide in patients with hepatopulmonary syndrome. Eur. Respir. J., 1995, 8 : 1883-1885.
15. ROLLA G., BRUSSINO L., COLAGRANDE P. et al. Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. Hepatology, 1997, 26 : 842-847.
16. ARGUEDAS M., DRAKE B., KAPOOR A., FALLON M. Carboxyhaemoglobin levels in cirrhotic patients with and without hepatopulmonary syndrome. Gastroenterology, 2005, 128 : 328-333.
17. RODRIGUEZ-ROISIN R., AGUSTI A.G., ROCA J. The hepatopulmonary syndrome : new name, old complexities. Thorax, 1992, 47 : 897-902.
18. FALLON M., ABRAMS G. Pulmonary dysfunction in chronic liver disease. Hepatology, 2000, 32 : 859-865.
19. VEDRINNE JM., DUPERRET S., BIZOLLON T., MAGNIN C., MOTIN J., TREPO C., DUCERF C. Comparison of transoesophageal and transthoracic contrast echocardiography for detection of an intrapulmonary shunt in liver disease. Chest, 1997, 111 : 1236-1240.
20. KOKSAL D., KACAR S., KOKSAL A., TUFEKCIOGLU O., KUCUKAY F., OKTEN S., SASMAZ N., ARDA K., SAHIN B. Evaluation of intrapulmonary vascular dilatations with high-resolution computed thorax tomography in patients with hepatopulmonary syndrome. J. Clin. Gastroenterol., 2006, 40 : 77-83.
21. GAINES D., FALLON M.B. Hepatopulmonary syndrome. Liver International, 2004, 24 : 397-401.
22. KROWKA M., MANDELL M., RAMSAY M et al. Hepatopulmonary syndrome and portopulmonary hypertension : a report of a multicenter liver transplant database. Liver Transpl., 2004, 10 : 174-182.
23. RUBIN L.J. Primary pulmonary hypertension. N. Engl. J. Med., 1997, 336 : 111-117.
24. MANTZ F., CRAIGE E. Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale. Arch. Pathol., 1951, 52 : 91-97.
25. HADENGUE A., BENHAYOUN M.K., LEBREC D., BENHAMOU J. Pulmonary hypertension complicating portal hypertension : prevalence and relation to splanchnic hemodynamics. Gastroenterology, 1991, 100 : 520-528.
26. RAMSAY M.A., SIMPSON B.R., NGUYEN A.T., RAMSAY K., EAST C., KLINTMALM G. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl. Surg., 1997, 3 : 494-500.
27. CASTRO M., KROWKA M.J., SCHROEDER D.R. et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin. Proc., 1996, 71 : 543-551.
28. JONES F.D., KUO P.C., JOHNSON L., NJOKU M., DIXON-FERGUSON M., PLOTKIN J. The coexistence of portopulmonary hypertension and hepatopulmonary syndrome. Anesthesiology, 1999, 90 : 626-629.
29. KASPAR M.D., RAMSAY M.A., SHUEY C.B., LEVY M. Jr., KLINTMALM G. Severe pulmonary hypertension and amelioration of hepatopulmonary syndrome after liver transplantation. Liver Transpl. Surg., 1998, 4 : 177-179.
30. MAL H., BURGIERE O., DURAND F., FARTOUKH M., COHEN-SOLAL A., FOURNIER M. Pulmonary hypertension following hepatopulmonary syndrome in a patient with cirrhosis. J. Hepatol., 1999, 31 : 360-364.
31. SCHRAUFNAGEL D.E., KAY J.M. Structural and pathologic changes in the lung vasculature in chronic liver disease. Clin. Chest Med., 1996, 17 : 1-15.
32. MC DONNELL P.J., TOYE P.A., HUTCHINS G.M. Primary pulmonary hypertension and cirrhosis : are they related ? Am. Rev. Respir. Dis., 1983, 127 : 437-441.
33. TUDER R.M., COOL C.D., GERACI M.W. et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med., 1999, 159 : 1925-1932.
34. GIAID A., SALEH D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med., 1995, 333 : 214-221.
35. EDDAHIBI S., RAFFESTIN B., CLOZEL M., LEVAME M., ADNOT S. Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am. J. Physiol., 1995, 268 : H828-H835.
36. RUBENS C., EWERT R., HALANK M. et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest, 2001, 120 : 1562-1569.
37. BUDHIRAJA R., HASSOUN P.M. Portopulmonary hypertension. A tale of two circulations. Chest, 2003, 123 : 562-576.
38. ROBALINO B.D., MOODIE D.S. Association between primary pulmonary hypertension and portal hypertension : analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J. Am. Coll. Cardiol., 1991, 17 : 492-498.
39. PILATIS N.D., JACOBS L.E., RERKPATTANAPIPAT P. et al. Clinical predictors of pulmonary hypertension in patients undergoing liver transplant evaluation. Liver Transpl., 2000, 6 : 85-91.
40. TORREGROSA M., GENESCA J., GONZALEZ A. et al. Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. Transplantation, 2001, 71 : 572-574.
41. KIM W.R., KROWKA M.J., PLEVAK D.J. et al. Accuracy of doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl., 2000, 6 : 453-458.
42. COLLE I., MOREAU R., GODINHO E. et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation : a prospective study. Hepatology, 2003, 2 : 401-409.
43. KROWKA M.J., PLEVAK D.J., FINDLAY J.Y., ROSEN C., WIESNER R., KROM R. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl., 2000, 6 : 443-450.
44. RAMSAY M.A. Perioperative mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl., 2000, 6 : 451-452.
45. PACKER M., MEDINA N., YUSHAK M. Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease. J. Am. Coll. Cardiol., 1984, 4 : 890-901.
46. WEIR E., RUBIN L., AYRES S. The acute administration of vasodilators in primary pulmonary hypertension : experience from the National Institutes of Health registry on primary pulmonary hypertension. Am. Rev. Respir. Dis., 1989, 140 : 1623-1630.
47. FINDLAY J., HARRISON B., PLEVAK D, KROWKA M. Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension. Liver Transpl. Surg., 1999, 5 : 381-387.
48. DE WOLF A., SCOTT V., BJERKE R et al. Hemodynamic effects of inhaled nitric oxide in four patients with severe liver disease and pulmonary hypertension. Liver Transpl. Surg., 1997, 3 : 594-597.
49. RAMSAY M., SCHMIDT A., HEIN H et al. Nitric oxide does not reverse pulmonary hypertension associated with end-stage liver disease : a preliminary report. Hepatology, 1997, 25 : 524-527.
50. GIRARDIS M., PASQUALOTTO A., COLO F. et al. Severe hypoxaemia and pulmonary hypertension during orthotopic liver transplantation : a successful use of inhaled nitric oxide. Intensive Care Med., 1999, 25 : 638.
51. MANDELL M., DUKE J. Nitric oxide reduces pulmonary hypertension during hepatic transplantation. Anesthesiology, 1994, 81 : 1538-1542.
52. RICH S., KAUFMANN E., LEVY P. The effects of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med., 1992, 327 : 76-81.
53. RICH S., BRUNDAGE B. High dose calcium channel blocking therapy for primary pulmonary hypertension : evidence for long term reduction in pulmonary artery pressure and regression of right ventricular hypertrophy. Circulation, 1987, 76 : 135-141.
54. KROWKA M., FRANTZ R., MCGOON M., SEVERSON C., PLEVAK D., WIESNER R. Improvement in pulmonary haemodynamics during intravenous epoprostenol (prostacyclin) : a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology, 1999, 30 : 641-648.
55. PLOTKIN J., KUO P., RUBIN L. et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation, 1998, 65 : 457-459.
56. FINDLAY J., PLEVAK D., KROWKA M., SACK E., PORAYKO M. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transpl. Surg., 1999, 5 : 362-365.
57. SIMONNEAU G., BARST R.J., GALIÉ N. et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med., 2002, 162 : 800-804.
58. GALIÉ N., HUMBERT M., VACHIÉRY J.L. et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension. J. Am. Coll. Cardiol., 2002, 39 : 1496-1502.
59. GALIE N., GHOFRANI H.A., TORBICKI A. et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med., 2005, 353 : 2148-2157.
60. COLLE I., DE VRIESE A., VAN VLIERBERGHE H., LAMEIRE N., DE VOS M. Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis, support for a risk in cirrhotic patients. Liver International, 2004, 24 : 63-68.
61. CHANNICK R., SIMONNEAU G., SITBON O. et al. Effects of dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension : a randomised placebo controlled study. Lancet, 2001, 358 : 1119-1123.
62. HOEPER M., HALANK M., MARX C. et al. Bosentan therapy for portopulmonary hypertension. Eur. Respir. J., 2005, 25 : 502-508.
63. MORTIER E., ONGENAE M., POELAERT J. et al. Rapidly progressive pulmonary artery hypertension and end-stage liver disease. Acta Anaesthesiol. Scand., 1996, 40 : 126-129.
64. DE CONINCK S., VAN VLIERBERGHE H., DE VOS M., ELEWAUT A. Review : hepatopulmonary syndrome and portopulmonary hypertension. Acta Gastroenterol. Belg., 2001, 64 : 286-94.
65. SCHOTT R., CHAOUAT A., LAUNOY A., POTTECHER T., WEITZENBLUM E. Improvement of pulmonary hypertension after liver transplantation. Chest, 1999, 115 : 1748-1749.
66. LEVY M.T, TORZILLO P., BOOKALLIL M., SHEIL A., MC CAUGHAN G. Case report : delayed resolution of severe pulmonary hypertension after isolated liver transplantation in a patient with cirrhosis. J. Gastroenterol. Hepatol., 1996, 11 : 734-737.
67. KUO P.C., PLOTKIN J.S., GAINE S. et al. Portopulmonary hypertension and the liver transplant candidate. Transplantation, 1999, 67 : 1087-1093.